Third Harmonic Bio’s initial public offering (NASDAQ:THRD) opened today for trading at $20.50 after pricing 10,900,000 shares of its common stock at $17 per share, the average expected range. The initial public offering volume was raised from 9,000,000 shares.
Morgan Stanley, Jefferies, Cowen and Lifesci Capital act as guarantors for the offer. Subscribers have a 30-day option to purchase up to 1,635,000 additional shares of common stock at the IPO price.
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing the next wave of medicine to treat allergic and inflammatory diseases.
/cloudfront-us-east-1.images.arcpublishing.com/advancelocal/AX4O4VF5X5E7JFGWBXLCP5FTN4.jpg)
